GeneOne Life Science, Inc.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1976-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.genels.com
Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: GLS-5300
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT02670187
- Locations
- πΊπΈ
Walter Reed Institute of Research, Silver Spring, Maryland, United States
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: VGX-6150
- First Posted Date
- 2014-01-03
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02027116
- Locations
- π°π·
Pusan National University Hospital, Pusan, Korea, Republic of
π°π·Yonsei University Severance Hospital, Seoul, Korea, Republic of
Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: VGX-3400
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- GeneOne Life Science, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01184976
- Locations
- π°π·
Korea University Anam Hospital, Seoul, Korea, Republic of
π°π·Yonsei University Severance Hospital, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath